{"id":15064,"date":"2023-01-19T01:36:34","date_gmt":"2023-01-19T00:36:34","guid":{"rendered":"https:\/\/www.immuninlab.ch\/?page_id=15064"},"modified":"2023-04-26T01:08:25","modified_gmt":"2023-04-25T23:08:25","slug":"medicaments-biologiques-et-anticorps-anti-medicaments","status":"publish","type":"page","link":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/","title":{"rendered":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments"},"content":{"rendered":"<div class=\"wpb-content-wrapper\" id=\"wpb-content-root\"><p>[vc_row][vc_column][vc_toggle title=&#8221;Infliximab (taux r\u00e9siduel et anticorps anti-infliximab)&#8221;]<strong>Nom commercial et biosimilaires<\/strong><\/p>\n<ul>\n<li>Remicade<\/li>\n<li>Remsima \/ Inflectra<strong><br \/>\n<\/strong><\/li>\n<\/ul>\n<p><strong>Description et informations cliniques<\/strong><\/p>\n<p>L&#8217;infliximab est un anticorps monoclonal chim\u00e9rique dirig\u00e9 contre le facteur de n\u00e9crose tumorale alpha (TNF-a). L&#8217;infliximab peut moduler le syst\u00e8me immunitaire par plusieurs m\u00e9canismes. L&#8217;infliximab inhibe directement le TNF-a en le neutralisant, induit l&#8217;apoptose cellulaire par une cytotoxicit\u00e9 cellulaire d\u00e9pendante des anticorps (ADCC) et une cytotoxicit\u00e9 d\u00e9pendante du compl\u00e9ment (CDC) et r\u00e9duit d&#8217;autres cytokines inflammatoires en activant les lymphocytes.<\/p>\n<p><strong>Objectif du test<\/strong><br \/>\nPendant le traitement par infliximab, une perte d&#8217;efficacit\u00e9 peut se produire en raison de la formation d&#8217;auto-anticorps contre l&#8217;infliximab (anticorps anti-drug, ADA). La d\u00e9termination du taux r\u00e9siduel d&#8217;infliximab, des anticorps anti-infliximab (ADA) et du TNF-a offre au m\u00e9decin traitant la possibilit\u00e9 d&#8217;accompagner le traitement et de l&#8217;optimiser de mani\u00e8re pr\u00e9coce.<\/p>\n<p><strong>Autorisation en Suisse (Swissmedic) pour le traitement des maladies auto-immunes suivantes avec l&#8217;infliximab :<\/strong><\/p>\n<ul>\n<li>Polyarthrite rhumato\u00efde<\/li>\n<li>Spondylarthrite ankylosante\/maladie de Bechterew<\/li>\n<li>Maladie de Crohn<\/li>\n<li>Colite ulc\u00e9reuse<\/li>\n<li>Psoriasis<\/li>\n<\/ul>\n<p><strong>Indications pour la mesure<\/strong><\/p>\n<p>Il est recommand\u00e9 de mesurer le taux r\u00e9siduel de l&#8217;infliximab en m\u00eame temps que les anticorps anti-infliximab (anticorps anti-drug, ADA) et le facteur de n\u00e9crose tumorale alpha (TNF-a).<br \/>\nPour mesurer correctement le taux r\u00e9siduel de l&#8217;infliximab et la concentration sanguine de TNF-a chez les patients trait\u00e9s, il est conseill\u00e9 de pr\u00e9lever le sang juste avant (24 heures maximum) la prochaine administration d&#8217;infliximab. Cela permet de r\u00e9duire les faux r\u00e9sultats n\u00e9gatifs dus \u00e0 l&#8217;interf\u00e9rence entre l&#8217;infliximab et le dosage immunologique pour la mesure du TNF-a (Publication\u00a0: Valaperti A. et al., <em>Journal of Pharmaceutical and Biomedical Analysis<\/em>, 2020).<\/p>\n<p><strong>Fr\u00e9quence<\/strong><\/p>\n<p>Une fois par semaine<\/p>\n<p><strong>Unit\u00e9 de mesure<\/strong><br \/>\nTaux r\u00e9siduel de l\u2019infliximab : \u00b5g\/mL<br \/>\nAnticorps anti-infliximab (anticorps anti-drug, ADA) : ng\/ml<\/p>\n<p><strong>Plages de r\u00e9f\u00e9rence<\/strong><br \/>\nTaux r\u00e9siduel de l\u2019infliximab : &gt; 0.0 \u00b5g\/ml<br \/>\nAnticorps anti-infliximab (anticorps anti-drug, ADA) : &lt; 0.0 ng\/ml<\/p>\n<p><strong>Points tarifaires<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"434\">TNF-a et anticorps<\/td>\n<td width=\"76\">Position<\/td>\n<td width=\"85\">P.tarifaires<\/td>\n<\/tr>\n<tr>\n<td width=\"434\">Cytokines\/mol\u00e9cules d\u2019adh\u00e9sion\/inhibiteurs de r\u00e9cepteurs, pour<br \/>\nle param\u00e8tre 1<\/td>\n<td width=\"76\">1474.10<\/td>\n<td width=\"85\">78.30<\/td>\n<\/tr>\n<tr>\n<td width=\"434\">Auto-anticorps, rares (1er param\u00e8tre)<\/td>\n<td width=\"76\">1194.00<\/td>\n<td width=\"85\">78.30<\/td>\n<\/tr>\n<tr>\n<td width=\"434\">Auto-anticorps, rares (2e param\u00e8tre)<\/td>\n<td width=\"76\">1194.00<\/td>\n<td width=\"85\">78.30<\/td>\n<\/tr>\n<tr>\n<td width=\"434\">TOTAL<\/td>\n<td width=\"76\"><\/td>\n<td width=\"85\">234.90<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Domaine de laboratoire : Immunologie<\/p>\n<p><strong>ANALYTIQUE<\/strong><\/p>\n<p><strong>M\u00e9thode<\/strong><\/p>\n<p>Enzyme-linked Immunosorbent Assay (ELISA)[\/vc_toggle][vc_toggle title=&#8221;Adalimumab (taux r\u00e9siduel et anticorps anti-adalimumab)&#8221;]<strong>Nom commercial et biosimilaires<\/strong><\/p>\n<ul>\n<li>Humira<\/li>\n<li>Abrilada \/ Amgevita \/ Hukyndra \/ Hulio \/ Hyrimoz \/ Idacio \/ Imraldi \/ Yuflyma<\/li>\n<\/ul>\n<p><strong>Description et informations cliniques<\/strong><\/p>\n<p>L&#8217;adalimumab est un anticorps monoclonal humain dirig\u00e9 contre le facteur de<br \/>\nn\u00e9crose tumorale alpha (TNF-a). L&#8217;adalimumab peut moduler le syst\u00e8me immunitaire par plusieurs m\u00e9canismes. L&#8217;adalimumab inhibe directement le TNF-a en le neutralisant, induit l&#8217;apoptose cellulaire par une cytotoxicit\u00e9 cellulaire d\u00e9pendante de l&#8217;anticorps (ADCC) et une cytotoxicit\u00e9 d\u00e9pendante du compl\u00e9ment (CDC) et r\u00e9duit d&#8217;autres cytokines inflammatoires en activant les lymphocytes.<\/p>\n<p><strong>Objectif du test<\/strong><\/p>\n<p>Pendant le traitement par l&#8217;adalimumab, une perte d&#8217;efficacit\u00e9 peut se produire en raison de la formation d&#8217;auto-anticorps contre l&#8217;adalimumab (anticorps anti-drug, ADA). La d\u00e9termination du taux r\u00e9siduel d&#8217;adalimumab, des anticorps anti-adalimumab (ADA) et du TNF-a offre au m\u00e9decin traitant la possibilit\u00e9 d&#8217;accompagner le traitement et de l&#8217;optimiser de nebi\u00e8re pr\u00e9coce.<\/p>\n<p><strong>Autorisation en Suisse (Swissmedic) pour le traitement des maladies auto-immunes suivantes avec l&#8217;adalimumab :<\/strong><\/p>\n<ul>\n<li>Maladie de Crohn<\/li>\n<li>Colite ulc\u00e9reuse<\/li>\n<li>Polyarthrite rhumato\u00efde<\/li>\n<li>Arthrite juv\u00e9nile idiopathique<\/li>\n<li>Arthrite psoriasique<\/li>\n<li>Psoriasis en plaques<\/li>\n<li>Hidrad\u00e9nite suppur\u00e9e<\/li>\n<li>Spondylarthrite ankylosante\/maladie de Bechterew<\/li>\n<\/ul>\n<p><strong>Indications pour la mesure<\/strong><\/p>\n<p>Il est recommand\u00e9 de mesurer le taux r\u00e9siduel de l&#8217;adalimumab en m\u00eame temps que les anticorps anti-adalimumab (anticorps anti-drug, ADA) et le facteur de n\u00e9crose tumorale alpha (TNF-a). Pour mesurer correctement le taux r\u00e9siduel d&#8217;adalimumab et la concentration sanguine de TNF-a chez les patients trait\u00e9s, il est conseill\u00e9 de pr\u00e9lever le sang juste avant (24 heures maximum) la prochaine administration d&#8217;adalimumab.<br \/>\nCela permet de r\u00e9duire les faux r\u00e9sultats n\u00e9gatifs caus\u00e9s par l&#8217;interf\u00e9rence entre l&#8217;adalimumab et le dosage immunologique pour la mesure du TNF-a (Publication : Valaperti A. et al., <em>Journal of Pharmaceutical and Biomedical Analysis<\/em>, 2020).<\/p>\n<p><strong>Fr\u00e9quence<\/strong><br \/>\nUne fois par semaine<\/p>\n<p><strong>Unit\u00e9 de mesure<\/strong><br \/>\nTaux r\u00e9siduel de l\u2019adalimumab : ng\/mL<br \/>\nAnticorps anti-adalimumab (anticorps anti-drug, ADA) : ng\/ml<\/p>\n<p><strong>Plages de r\u00e9f\u00e9rence<\/strong><br \/>\nTaux r\u00e9siduel de l\u2019adalimumab : &gt; 0.0 ng\/ml<br \/>\nAnticorps anti-adalimumab (anticorps anti-drug, ADA) : &lt; 0.0 ng\/ml<\/p>\n<p><strong>Points tarifaires<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"434\">TNF-a et anticorps<\/td>\n<td width=\"76\">Position<\/td>\n<td width=\"85\">P.tarifaires<\/td>\n<\/tr>\n<tr>\n<td width=\"434\">Cytokines\/mol\u00e9cules d\u2019adh\u00e9sion\/inhibiteurs de r\u00e9cepteurs, pour<br \/>\nle param\u00e8tre 1<\/td>\n<td width=\"76\">1474.10<\/td>\n<td width=\"85\">78.30<\/td>\n<\/tr>\n<tr>\n<td width=\"434\">Auto-anticorps, rares (1er param\u00e8tre)<\/td>\n<td width=\"76\">1194.00<\/td>\n<td width=\"85\">78.30<\/td>\n<\/tr>\n<tr>\n<td width=\"434\">Auto-anticorps, rares (2e param\u00e8tre)<\/td>\n<td width=\"76\">1194.00<\/td>\n<td width=\"85\">78.30<\/td>\n<\/tr>\n<tr>\n<td width=\"434\">TOTAL<\/td>\n<td width=\"76\"><\/td>\n<td width=\"85\">234.90<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Domaine de laboratoire : Immunologie<\/p>\n<p><strong>ANALYTIQUE<\/strong><\/p>\n<p><strong>M\u00e9thode<\/strong><\/p>\n<p>Enzyme-linked Immunosorbent Assay (ELISA)[\/vc_toggle][vc_toggle title=&#8221;Vedolizumab (taux r\u00e9siduel et anticorps anti-vedolizumab)&#8221;]<strong>Nom commercial et biosimilaires<\/strong><\/p>\n<ul>\n<li>Entyvio<\/li>\n<li>Pas encore de biosimilaires<strong><br \/>\n<\/strong><\/li>\n<\/ul>\n<p><strong>Description et informations cliniques<\/strong><\/p>\n<p>Le vedolizumab est un anticorps monoclonal humanis\u00e9 dirig\u00e9 contre l&#8217;int\u00e9grine-alpha-4\/beta-7 (a4b7). En se liant \u00e0 l&#8217;int\u00e9grine-a4b7 sur les lymphocytes qui p\u00e9n\u00e8trent dans la paroi intestinale, le vedolizumab exerce un effet immunosuppresseur sp\u00e9cifiquement sur l&#8217;intestin.<\/p>\n<p><strong>Objectif du test<\/strong><br \/>\nPendant le traitement par vedolizumab, une perte d&#8217;efficacit\u00e9 peut se produire en raison de la formation d&#8217;auto-anticorps contre le vedolizumab (anticorps anti-drug, ADA). La d\u00e9termination du taux r\u00e9siduel du vedolizumab et des anticorps anti-vedolizumab (ADA) offre au m\u00e9decin traitant la possibilit\u00e9 d&#8217;accompagner le traitement et de l&#8217;optimiser de mani\u00e8re pr\u00e9coce.<\/p>\n<p><strong>Autorisation en Suisse (Swissmedic) pour le traitement des maladies auto-immunes suivantes avec le vedolizumab :<\/strong><\/p>\n<ul>\n<li>Colite ulc\u00e9reuse<\/li>\n<li>Maladie de Crohn<\/li>\n<\/ul>\n<p><strong>Indications pour la mesure<\/strong><br \/>\nPour mesurer correctement le taux r\u00e9siduel du vedolizumab chez les patients trait\u00e9s, il est conseill\u00e9 de pr\u00e9lever le sang juste avant (24 heures maximum) la prochaine administration de vedolizumab.<\/p>\n<p><strong>Fr\u00e9quence<\/strong><br \/>\nUne fois par semaine<\/p>\n<p><strong>Unit\u00e9 de mesure<\/strong><br \/>\nTaux r\u00e9siduel du vedolizumab : ng\/mL<br \/>\nAnticorps anti-vedolizumab (anticorps anti-drug, ADA) : ng\/ml<\/p>\n<p><strong>Plages de r\u00e9f\u00e9rence<\/strong><br \/>\nTaux r\u00e9siduel du vedolizumab : &gt; 0.0 ng\/ml<br \/>\nAnticorps anti-vedolizumab (anticorps anti-drug, ADA) : &lt; 0.0 ng\/ml<\/p>\n<p><strong>Points tarifaires<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"434\">Anticorps<\/td>\n<td width=\"76\">Position<\/td>\n<td width=\"85\">P.tarifaires<\/td>\n<\/tr>\n<tr>\n<td width=\"434\">Auto-anticorps, rares (1er param\u00e8tre)<\/td>\n<td width=\"76\">1194.00<\/td>\n<td width=\"85\">78.30<\/td>\n<\/tr>\n<tr>\n<td width=\"434\">Auto-anticorps, rares (2e param\u00e8tre)<\/td>\n<td width=\"76\">1194.00<\/td>\n<td width=\"85\">78.30<\/td>\n<\/tr>\n<tr>\n<td width=\"434\">TOTAL<\/td>\n<td width=\"76\"><\/td>\n<td width=\"85\">156.60<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Domaine de laboratoire : Immunologie<\/p>\n<p><strong>ANALYTIQUE<\/strong><\/p>\n<p><strong>M\u00e9thode<\/strong><br \/>\nEnzyme-linked Immunosorbent Assay (ELISA)[\/vc_toggle][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_toggle title=&#8221;Infliximab (taux r\u00e9siduel et anticorps anti-infliximab)&#8221;]Nom commercial et biosimilaires Remicade Remsima \/ Inflectra Description et informations cliniques L&#8217;infliximab est un anticorps monoclonal chim\u00e9rique dirig\u00e9 contre le facteur de n\u00e9crose [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":14961,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"rs_blank_template":"","rs_page_bg_color":"","slide_template_v7":"","footnotes":""},"class_list":["post-15064","page","type-page","status-publish","hentry"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t<meta name=\"description\" content=\"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments - Immuninlab\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"google-site-verification\" content=\"3R9O66seASf_SGfs6pGZHMU8FMe9-ItkEDwLW6JeyFQ\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.3\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Immuninlab | klinisch-immunologisches Labor Z\u00fcrich\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments | Immuninlab\" \/>\n\t\t<meta property=\"og:description\" content=\"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments - Immuninlab\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2023-01-19T00:36:34+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2023-04-25T23:08:25+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments | Immuninlab\" \/>\n\t\t<meta name=\"twitter:description\" content=\"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments - Immuninlab\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/medicaments-biologiques-et-anticorps-anti-medicaments\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/#listItem\",\"name\":\"Prestations\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/#listItem\",\"position\":2,\"name\":\"Prestations\",\"item\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/medicaments-biologiques-et-anticorps-anti-medicaments\\\/#listItem\",\"name\":\"M\\u00e9dicaments biologiques et anticorps anti-m\\u00e9dicaments\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/medicaments-biologiques-et-anticorps-anti-medicaments\\\/#listItem\",\"position\":3,\"name\":\"M\\u00e9dicaments biologiques et anticorps anti-m\\u00e9dicaments\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/#listItem\",\"name\":\"Prestations\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/#organization\",\"name\":\"Immuninlab\",\"description\":\"klinisch-immunologisches Labor Z\\u00fcrich\",\"url\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/\",\"telephone\":\"+41445442821\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.immuninlab.ch\\\/wheevoog\\\/2022\\\/12\\\/IML-Logo.png\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/medicaments-biologiques-et-anticorps-anti-medicaments\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/medicaments-biologiques-et-anticorps-anti-medicaments\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/\",\"https:\\\/\\\/x.com\\\/\",\"https:\\\/\\\/instagram.com\\\/\",\"https:\\\/\\\/pinterest.com\\\/\",\"https:\\\/\\\/youtube.com\\\/\",\"https:\\\/\\\/linkedin.com\\\/in\\\/\"]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/medicaments-biologiques-et-anticorps-anti-medicaments\\\/#webpage\",\"url\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/medicaments-biologiques-et-anticorps-anti-medicaments\\\/\",\"name\":\"M\\u00e9dicaments biologiques et anticorps anti-m\\u00e9dicaments | Immuninlab\",\"description\":\"M\\u00e9dicaments biologiques et anticorps anti-m\\u00e9dicaments - Immuninlab\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/prestations\\\/medicaments-biologiques-et-anticorps-anti-medicaments\\\/#breadcrumblist\"},\"datePublished\":\"2023-01-19T01:36:34+01:00\",\"dateModified\":\"2023-04-26T01:08:25+02:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/\",\"name\":\"Immuninlab\",\"alternateName\":\"Immuninlab\",\"description\":\"klinisch-immunologisches Labor Z\\u00fcrich\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.immuninlab.ch\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t\n\n","aioseo_head_json":{"title":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments | Immuninlab","description":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments - Immuninlab","canonical_url":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"3R9O66seASf_SGfs6pGZHMU8FMe9-ItkEDwLW6JeyFQ","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.immuninlab.ch\/fr\/#listItem","position":1,"name":"Home","item":"https:\/\/www.immuninlab.ch\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.immuninlab.ch\/fr\/prestations\/#listItem","name":"Prestations"}},{"@type":"ListItem","@id":"https:\/\/www.immuninlab.ch\/fr\/prestations\/#listItem","position":2,"name":"Prestations","item":"https:\/\/www.immuninlab.ch\/fr\/prestations\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/#listItem","name":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.immuninlab.ch\/fr\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/#listItem","position":3,"name":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments","previousItem":{"@type":"ListItem","@id":"https:\/\/www.immuninlab.ch\/fr\/prestations\/#listItem","name":"Prestations"}}]},{"@type":"Organization","@id":"https:\/\/www.immuninlab.ch\/fr\/#organization","name":"Immuninlab","description":"klinisch-immunologisches Labor Z\u00fcrich","url":"https:\/\/www.immuninlab.ch\/fr\/","telephone":"+41445442821","logo":{"@type":"ImageObject","url":"https:\/\/www.immuninlab.ch\/wheevoog\/2022\/12\/IML-Logo.png","@id":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/#organizationLogo"},"image":{"@id":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/#organizationLogo"},"sameAs":["https:\/\/facebook.com\/","https:\/\/x.com\/","https:\/\/instagram.com\/","https:\/\/pinterest.com\/","https:\/\/youtube.com\/","https:\/\/linkedin.com\/in\/"]},{"@type":"WebPage","@id":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/#webpage","url":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/","name":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments | Immuninlab","description":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments - Immuninlab","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/www.immuninlab.ch\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/#breadcrumblist"},"datePublished":"2023-01-19T01:36:34+01:00","dateModified":"2023-04-26T01:08:25+02:00"},{"@type":"WebSite","@id":"https:\/\/www.immuninlab.ch\/fr\/#website","url":"https:\/\/www.immuninlab.ch\/fr\/","name":"Immuninlab","alternateName":"Immuninlab","description":"klinisch-immunologisches Labor Z\u00fcrich","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/www.immuninlab.ch\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"Immuninlab | klinisch-immunologisches Labor Z\u00fcrich","og:type":"article","og:title":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments | Immuninlab","og:description":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments - Immuninlab","og:url":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/","article:published_time":"2023-01-19T00:36:34+00:00","article:modified_time":"2023-04-25T23:08:25+00:00","twitter:card":"summary_large_image","twitter:title":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments | Immuninlab","twitter:description":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments - Immuninlab"},"aioseo_meta_data":{"post_id":"15064","title":null,"description":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments - Immuninlab","keywords":[],"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":[],"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-04-25 22:28:29","updated":"2026-05-15 05:42:27","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.immuninlab.ch\/fr\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.immuninlab.ch\/fr\/prestations\/\" title=\"Prestations\">Prestations<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tM\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.immuninlab.ch\/fr\/"},{"label":"Prestations","link":"https:\/\/www.immuninlab.ch\/fr\/prestations\/"},{"label":"M\u00e9dicaments biologiques et anticorps anti-m\u00e9dicaments","link":"https:\/\/www.immuninlab.ch\/fr\/prestations\/medicaments-biologiques-et-anticorps-anti-medicaments\/"}],"_links":{"self":[{"href":"https:\/\/www.immuninlab.ch\/fr\/wp-json\/wp\/v2\/pages\/15064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.immuninlab.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.immuninlab.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.immuninlab.ch\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.immuninlab.ch\/fr\/wp-json\/wp\/v2\/comments?post=15064"}],"version-history":[{"count":0,"href":"https:\/\/www.immuninlab.ch\/fr\/wp-json\/wp\/v2\/pages\/15064\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.immuninlab.ch\/fr\/wp-json\/wp\/v2\/pages\/14961"}],"wp:attachment":[{"href":"https:\/\/www.immuninlab.ch\/fr\/wp-json\/wp\/v2\/media?parent=15064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}